Dexmedetomidine Supplemented Analgesia and Delirium After Hip Fracture Surgery

Phase 4TerminatedNCT04955249

Peking University First Hospital67 enrolled

Overview

Delirium is common in the elderly after hip fracture surgery, and is associated with worse outcomes. The investigators hypothesize that, for elderly patients after hip fracture surgery, dexmedetomidine supplemented analgesia can reduce the incidence of delirium and improve the long-term outcomes.

Delirium is a common complication in patients after hip fracture surgery and is associated with worse outcomes, including prolonged hospital stay, poor functional recovery, decreased cognitive function, increased health care costs, and elevated mortality rate. The etiology of delirium is multifactorial and include severe pain and sleep disturbances after surgery, as well as surgery-related inflammation. Dexmedetomidine is a selective alpha 2 receptor agonist. It exerts sedative effects by activating the endogenous sleep-promoting pathway and leads to a state like non-rapid eye movement sleep. It produces analgesic effects by activating the alpha2a adrenergic receptor subtype in the spinal cord. Perioperative dexmedetomidine also alleviates the degree of surgery-related inflammation. Previous studies showed that, for elderly patients admitted to the intensive care unit after non-cardiac surgery, low-dose dexmedetomidine infusion improved subjective sleep quality and reduced delirium early after surgery; it also increased survival up to 2 years and improved life quality in 3-year survivors. The investigators hypothesize that dexmedetomidine supplemented patient-controlled analgesia can also reduce delirium and improve long-term outcomes in elderly patients after hip fracture surgery.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Enrollment

Conditions

Elderly Hip Fracture Surgery Patient-controlled Analgesia Dexmedetomidine Postoperative Delirium

Interventions

DexmedetomidineDRUG

Patients in this group receive dexmedetomidine-supplemented patient-controlled analgesia for up to 3 days after surgery. The formula is a mixture of dexmedetomidine (1 microgram/ml) and sufentanil (1 microgram/ml), diluted with normal saline to 200 ml. The analgesic pump is programmed to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.

PlaceboDRUG

Patients in this group receive routine patient-controlled intravenous analgesia for up to 3 days after surgery. The formula is a mixture of placebo and sufentanil (1 microgram/ml), diluted with normal saline to 200 ml. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.

Eligibility

Sex: ALLMin age: 65 YearsMax age: 89 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥ 65 years but \< 90 years; * Scheduled to undergo hip fracture surgery; * Planned to use patient-controlled intravenous analgesia (PCIA) after surgery. Exclusion Criteria: * Refuse to participate in this study; * Preoperative history of schizophrenia, epilepsy, Parkinsonism, or myasthenia gravis; * Inability to communicate in the preoperative period because of coma, profound dementia or language barrier; * Preoperative obstructive sleep apnea (diagnosed sleep apnea syndrome or a STOP-Bang score ≥3 combined with a serum bicarbonate ≥28 mmol/L); * Sick sinus syndrome, severe sinus bradycardia (\< 50 beats per minute), or second-degree or above atrioventricular block without pacemaker; * Severe hepatic dysfunction (Child-Pugh class C); * Severe renal dysfunction (requirement of renal replacement therapy before surgery); * American Society of Anesthesiologists physical status \>IV, or estimated survival ≤24 h.

Locations (1)

Peking University First Hospital

Beijing, China

Outcomes

Primary Outcomes

Incidence of delirium within the first 5 days after surgery

Delirium is assessed twice daily (8:00-10:00 am, 18:00-20:00 pm) with the 3-minute Diagnostic Confusion Assessment Method (3D CAM, for patients without mechanical ventilation) or the Confusion Assessment Method for the intensive care unit (CAM-ICU, for patients with mechanical ventilation) during postoperative days 1-5.

Time frame: Up to 5 days after surgery

Secondary Outcomes

Daily prevalence of delirium during the first 5 days after surgery

Time frame: Up to 5 days after surgery

Length of stay in hospital after surgery

Time frame: Up to 30 days after surgery

Incidence of non-delirium complications within 30 days after surgery

Non-delirium complications are defined as new-onset medical events other than delirium that are harmful to patients' recovery and required therapeutic intervention, i.e., grade II or above on the Clavien-Dindo classification.

Time frame: Up to 30 days after surgery

All-cause 30-day mortality

Time frame: Up to 30 days after surgery

Quality of life at 30 days

Quality of life is assessed with the WHOQOL-BREF, a 24-item questionnaire that provides assessments of the quality of life in physical, psychological, social relationship, and environmental domains. For each domain, the score ranges from 0 to 100, with higher score indicating better function.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.